1. Home
  2. CELC vs ANSC Comparison

CELC vs ANSC Comparison

Compare CELC & ANSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • ANSC
  • Stock Information
  • Founded
  • CELC 2011
  • ANSC 2021
  • Country
  • CELC United States
  • ANSC United States
  • Employees
  • CELC N/A
  • ANSC N/A
  • Industry
  • CELC Medical Specialities
  • ANSC
  • Sector
  • CELC Health Care
  • ANSC
  • Exchange
  • CELC Nasdaq
  • ANSC Nasdaq
  • Market Cap
  • CELC 440.0M
  • ANSC 466.6M
  • IPO Year
  • CELC 2017
  • ANSC 2023
  • Fundamental
  • Price
  • CELC $57.43
  • ANSC $10.94
  • Analyst Decision
  • CELC Strong Buy
  • ANSC
  • Analyst Count
  • CELC 5
  • ANSC 0
  • Target Price
  • CELC $53.60
  • ANSC N/A
  • AVG Volume (30 Days)
  • CELC 906.9K
  • ANSC 13.9K
  • Earning Date
  • CELC 08-14-2025
  • ANSC 01-01-0001
  • Dividend Yield
  • CELC N/A
  • ANSC N/A
  • EPS Growth
  • CELC N/A
  • ANSC N/A
  • EPS
  • CELC N/A
  • ANSC 0.14
  • Revenue
  • CELC N/A
  • ANSC N/A
  • Revenue This Year
  • CELC N/A
  • ANSC N/A
  • Revenue Next Year
  • CELC N/A
  • ANSC N/A
  • P/E Ratio
  • CELC N/A
  • ANSC $80.15
  • Revenue Growth
  • CELC N/A
  • ANSC N/A
  • 52 Week Low
  • CELC $7.58
  • ANSC $10.32
  • 52 Week High
  • CELC $63.06
  • ANSC $10.94
  • Technical
  • Relative Strength Index (RSI)
  • CELC 64.38
  • ANSC 66.77
  • Support Level
  • CELC $50.44
  • ANSC $10.90
  • Resistance Level
  • CELC $63.06
  • ANSC $10.87
  • Average True Range (ATR)
  • CELC 3.17
  • ANSC 0.01
  • MACD
  • CELC -0.47
  • ANSC 0.00
  • Stochastic Oscillator
  • CELC 60.71
  • ANSC 100.00

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About ANSC Agriculture & Natural Solutions Acquisition Corporation

Agriculture & Natural Solutions Acquisition Corp is a blank check company.

Share on Social Networks: